<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104379">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02128061</url>
  </required_header>
  <id_info>
    <org_study_id>SENIOR</org_study_id>
    <nct_id>NCT02128061</nct_id>
  </id_info>
  <brief_title>Efficacy of Lenalidomide in Combination With SC Rituximab + miniCHOP in DLBCL Patients of 80 Years Old or More</brief_title>
  <official_title>Sub-cutaneous Rituximab-miniCHOP Versus Sub-cutaneous Rituximab-miniCHOP + Lenalinomide (R2-miniCHOP) in Diffuse Large B Cell Lymphoma for Patients of 80 Years Old or More. A Multicentric Phase III Study of the LYSA.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Lymphoma Academic Research Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Lymphoma Academic Research Organisation</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy of R2-miniCHOP (Sub-cutaneous
      Rituximab-miniCHOP + lenalidomide) and R-miniCHOP (Sub-cutaneous Rituximab-miniCHOP) in
      patients aged 80 years old or more with not previously treated CD20+ diffuse large B-cell
      lymphoma as measured by the overall survival (OS).The SENIOR trial will evaluate the
      tolerance and efficacy of the combination of the R2-miniCHOP regimen and compare this
      experimental arm to the standard R-miniCHOP regimen.The statistical plan is based on the
      hypothesis of an increase by 15% of the 2y-OS in favor of the experimental arm, as compared
      to the reference arm (R-miniCHOP).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The overall survival (OS)</measure>
    <time_frame>OS rates at 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>OS will be measured from the date of randomization to the date of death from any cause. Alive patients will be censored at their last contact.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>PFS rates at 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>PFS is defined as the time from randomization into the study to the first observation of documented disease progression/relapse or death due to any cause. If a subject has not progressed or died, PFS will be censored at the time of last visit with adequate assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-Free Survival (EFS)</measure>
    <time_frame>EFS rates at 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>EFS will be measured from the date of randomization to the date of first documented disease progression/relapse (Cheson 1999), initiation of new anti-lymphoma therapy or death from any cause. Patients without documented event at the time of analysis will be censored at their visit with adequate assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>DoR rates at 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>DoR will be measured from the time of attainment of CR/CRu or PR to the date of first documented disease progression/relapse or death from any cause. Patients alive and free of progression will be censored at their last visit with adequate assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-Free Survival (DFS)</measure>
    <time_frame>DFS rates at 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>DFS will be measured from the date of attainment of a complete or unconfirmed complete response (at the end of treatment or at permanent treatment discontinuation evaluation) to the date of first observation of documented disease progression or death due to any cause. CR/CRu patients who have not progressed or died will be censored at the time of last visit with adequate assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS according to GCB/non-GCB phenotype</measure>
    <time_frame>OS according to GCB/non-GCB phenotype rates at 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>OS will be described for the R2-miniCHOP group according to Hans algorithm (GCB/non-GCB phenotype).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate at the end of treatment</measure>
    <time_frame>22 weeks (28 days after the end of the 6, three-weeks interval, cycles of treatment) or within 28 days following permanent treatment discontinuation</time_frame>
    <safety_issue>No</safety_issue>
    <description>Disease response evaluation at end of treatment (after 6 cycles) will be used to determine the Response Rate. Response will be assessed at end of treatment (after end of the 6th cycle of treatment or at permanent treatment discontinuation).
Assessment of response will be based on the International Workshop to Standardize Response criteria for NHL (Criteria for evaluation of response in Non-Hodgkin's lymphoma (Cheson, 1999)).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Simplified Geriatric Scales</measure>
    <time_frame>At baseline</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Four geriatric tools will be performed before any chemotherapy administration (IADL, MNA, G8, and CIRS-G scales). Each scale will be analyzed in order to have a picture of the population at baseline. Thereafter, the prognosis impact in OS and PFS of each scale will be evaluated using univariate (Kaplan Meier) and multivariate analyses (Cox model). Safety analyses will also be performed according to each scale in order to evaluate the toxicity predictive power of these scales.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HRQOL</measure>
    <time_frame>At randomization and 22 weeks after Day 1 of Cycle 1 of R-miniCHOP or R2-miniCHOP (28 days after the end of the 6, three-weeks interval, cycles of treatment)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Health related Quality of Life will be assessed by the QLQ-C30 and the QLQ-ELD14 at randomization and at end of treatment. The improvement or not of the QoL will therefore be assessed.
The QLQ-ELD14 was developed to supplement the QLQ-C30 for measuring HRQoL in patients aged &gt;70 years in oncology studies.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Diffuse Large B Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>R-miniCHOP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All patients will be treated with R-miniCHOP at a three-weeks interval for 6 cycles CYCLOPHOSPHAMIDE IV: 400 mg/m² D1 - DOXORUBICINE IV : 25 mg/m² D1 - VINCRISTINE IV : 1 mg TD D1 - PREDNISONE PO : 40 mg/m² D1 to D5 - RITUXIMAB SC* : 1400 mg TD D1
*The first cycle of rituximab is delivered by IV at the dose of 375 mg/m2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R2-miniCHOP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will be treated with R2-miniCHOP at a three-weeks interval for 6 cycles CYCLOPHOSPHAMIDE IV: 400 mg/m² D1 - DOXORUBICINE IV : 25 mg/m² D1 - VINCRISTINE IV : 1 mg TD D1 - PREDNISONE PO : 40 mg/m² D1 to D5 - RITUXIMAB SC* : 1400 mg TD D1 LENALIDOMIDE PO** :10 mg TD D1 to D14
*The first cycle of rituximab is delivered by IV at the dose of 375 mg/m2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <arm_group_label>R2-miniCHOP</arm_group_label>
    <other_name>Revlimid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <arm_group_label>R-miniCHOP</arm_group_label>
    <arm_group_label>R2-miniCHOP</arm_group_label>
    <other_name>Mabthera</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with histologically proven CD20+ diffuse large B-cell lymphoma (DLBCL) (WHO
             classification 2008) including all clinical subtypes (primary mediastinal,
             intravascular, etc…), with all aaIPI.

        May also be included: De Novo transformed DLBCL from low grade lymphoma (Follicular,
        other...) and DLBCL associated with some small cell Infiltration in bone marrow or lymph
        node; or CD20+ B-cell lymphoma, with intermediate features between DLBCL and Burkitt or
        with intermediate features between DLBCL and classical Hodgkin lymphoma; or CD20+
        Follicular lymphoma grade 3B; or CD20+ Aggressive B-cell lymphoma unclassifiable.

          -  With a CD10 immunostaining performed by the participating center pathologist

          -  Aged ≥ 80 years old

          -  Ann Arbor stage II, III or IV

          -  Patient previously untreated for DLBCL Lymphoma

          -  ECOG performance status ≤ 2

          -  With a minimum life expectancy of 3 months

          -  Negative HIV, HBV (anti-HBc negativity) and HCV serologies test within 4 weeks before
             inclusion (except after vaccination)

          -  Patient able to give his consent and having signed a written Informed consent

          -  Patient affiliated to social security system, if applicable

          -  Male patients must practice complete abstinence or agree to use a condom during
             sexual contact  with a pregnant female or a female of childbearing potential while
             participating in the study, during dose interruptions, and for 3 months following
             study drug discontinuation, even if he has undergone a successful vasectomy.

          -  All patients must agree to fulfill the global Lenalidomide Pregnancy Prevention Risk
             Management Plan as applicable according to the randomization arm (randomization arm)

        Exclusion Criteria:

          -  Any other histological type of lymphoma, Burkitt included

          -  Any history of treated or non-treated small-B cell lymphoma

          -  Central nervous system or meningeal involvement by lymphoma

          -  Contra-indication to any drug contained in the chemotherapy regimens ; for
             anthracycline use, ejection fraction should be &gt; 50%

          -  Any serious active disease (according to the investigator's decision)

          -  History of deep venous thrombosis or arterial thromboembolism events within the past
             12 months before inclusion

          -  Poor renal function (creatinine clearance &lt; 40 ml/min, according to MDRD formula)

          -  Poor hepatic function (total bilirubin level &gt;30mmol/l, transaminases &gt;2.5 maximum
             normal level) unless these abnormalities are related to the lymphoma

          -  Poor bone marrow reserve as defined by neutrophils &lt;1.5 G/l or platelets &lt;100 G/l,
             unless related to bone marrow infiltration

          -  Any history of cancer during the last 5 years with the exception of non-melanoma skin
             tumors or stage 0 (in situ) cervical carcinoma Patients previously diagnosed with
             prostate cancer are eligible if (1) their disease was T1-T2a, N0, M0, with a Gleason
             score ≤7, and a prostate specific antigen (PSA) ≤10 ng/mL prior to initial therapy,
             (2) they had definitive curative therapy (i.e., prostatectomy or radiotherapy) 2
             years before Day 1 of Cycle 1, and (3) at a minimum 2 years following therapy they
             had no clinical evidence of prostate cancer, and their PSA was undetectable if they
             underwent prostatectomy or &lt;1 ng/mL if they did not undergo prostatectomy

          -  Treatment with any investigational drug within 30 days before planned first cycle of
             chemotherapy and during the study

          -  Prior treatment with anti-CD20 monoclonal antibody or alemtuzumab within 3 months
             prior to start of therapy

          -  Prior use of lenalidomide

          -  Prior ≥ Grade 3 allergic reaction/hypersensitivity to thalidomide

          -  Prior ≥ Grade 3 rash or any desquamating (blistering) rash while taking thalidomide

          -  Subjects with ≥ Grade 2 neuropathy

          -  Adult patient under tutelage

          -  Female of childbearing potential are excluded. (Note: Females are defined as not of
             childbearing potential if there is documentation of &quot;natural menopause for at least
             24 consecutive months, a hysterectomy or bilateral oophorectomy&quot;)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>80 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabrice Jardin, MD,Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Lymphoma Study Association - LYSA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stéphane Vincent, PharmD</last_name>
    <phone>+33 (0) 4 27 01 27 35</phone>
    <email>stephane.vincent@lysarc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fontanet BIJOU, MD</last_name>
      <email>f.bijou@bordeaux.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Fontanet BIJOU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Châlon sur Sâone</name>
      <address>
        <city>Châlon sur Sâone</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurent VOILLAT, MD</last_name>
      <email>laurent.voillat@ch-chalon71.fr</email>
    </contact>
    <investigator>
      <last_name>Laurent VOILLAT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU d'Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric HERMET, MD</last_name>
      <email>ehermet@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Eric HERMET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP - Hopital Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Corinne HAIOUN, MD, Prof</last_name>
      <email>corinne.haioun@hmn.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Corinne HAIOUN, MD, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon - Hôpital le Bocage</name>
      <address>
        <city>Dijon</city>
        <zip>21034</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier CASASNOVAS, MD</last_name>
      <email>olivier.casasnovas@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier CASASNOVAS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rémy GRESSIN, MD</last_name>
      <email>rgressin@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Rémy GRESSIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Versailles - Hopital André Mignot</name>
      <address>
        <city>Le Chesnay</city>
        <zip>78157</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hassan Farhat, MD</last_name>
      <email>hfarhat@ch-versailles.fr</email>
    </contact>
    <investigator>
      <last_name>Hassan FARHAT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Lille - Hôpital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Franck MORSCHHAUSER, MD, Prof</last_name>
      <email>franck.morschhauser@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Franck MORSCHHAUSER, MD, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hervé GHESQUIERES, MD</last_name>
      <email>herve.ghesquieres@lyon.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Hervé GHESQUIERES, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Steven LEGOUILL, MD, Prof</last_name>
      <email>steven.legouill@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Steven LEGOUILL, MD, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frédéric PEYRADE, MD</last_name>
      <email>frederic.peyrade@nice.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Frédéric PEYRADE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Catherine THIEBLEMONT, MD, Prof</last_name>
      <email>catherine.thieblemont@sls.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Catherine THIEBLEMONT, MD, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Necker</name>
      <address>
        <city>Paris</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Richard DELARUE, MD</last_name>
      <email>richard.delarue@nck.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Richard DELARUE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU du Haut Leveque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kamal BOUABDALLAH, MD</last_name>
      <email>krimo.bouabdallah@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Kamal BOUABDALLAH, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gilles SALLES, MD, Prof</last_name>
      <email>gilles.salles@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Gilles Salles, MD, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thierry LAMY, MD</last_name>
      <email>thierry.lamy.de.la.chapelle@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Thierry LAMY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hervé TILLY, MD, Prof</last_name>
      <email>herve.tilly@chb.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Hervé TILLY, MD, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Rouen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe FRUCHART, MD</last_name>
      <email>c.fruchart@baclesse.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Christophe FRUCHART, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre René Huguenin - Institut Curie</name>
      <address>
        <city>Saint-Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sandra MALAK, MD</last_name>
      <email>sandra.malak@curie.net</email>
    </contact>
    <investigator>
      <last_name>Sandra MALAK, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Purpan - Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clément GAUDIN, MD</last_name>
      <email>gaudin.c@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Clément GAUDIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hélène MONJANEL, MD</last_name>
      <email>helene.monjanel@univ-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Hélène MONJANEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Brabois</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Serge BOLOGNA, MD, Prof</last_name>
      <email>s.bologna@chu-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>Serge BOLOGNA, MD, prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 29, 2014</lastchanged_date>
  <firstreceived_date>April 23, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
